After obtaining her PhD degree, Carmen Paradas completed two postdoctoral fellowships with Dr. Hirano and Dr. DiMauro at Columbia University (NYC) and Dr Nishino at National Center of Neurology and Psychiatry (Tokyo). From 2014, Dr Paradas is responsible for the ALS Unit at Hospital Universitario Virgen del Rocío (Sevilla), designated National (CSUR) and European (EURO-NMD) reference unit, closely collaborating with the rest of ALS Units in Andalucía. Her group is also part of the Spanish network for the study of neurodegenerative disorders (CIBERNED) and the international TREAT-NMD network, and a member of the principals learned societies where ALS is a main topic.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.